Revolutionizing Spine Surgery with Backpack® Bone Graft System
Ventris Medical, known for its innovative approach in orthobiologics, has made significant strides in enhancing surgical outcomes for spinal procedures. The company has recently achieved an important milestone by securing 510(k) clearance from the United States Food and Drug Administration (FDA) for its Backpack® Bone Graft. This approval marks a critical step in the integration of advanced biomaterials designed specifically for the intervertebral disc space. The new Backpack® offers two distinct versions featuring innovative materials aimed at improving healing processes during and after surgery.
Understanding the Backpack® Variants
Backpack® AF with Allocell® AF Allograft Fibers
The Backpack® AF is unique in its design, utilizing a 100% biologic graft system that leverages osteoinductive allograft fibers sealed within a collagen mesh pouch. This remarkable fusion allows for streamlined healing as both the pouch and fibers work synergistically in the bone remodeling process. The structure of the Allocell® AF fibers promotes cell attachment and growth, facilitating natural healing. An added benefit is the convenience of a ported pouch designed for hydration, making it simple and efficient for surgical teams to use.
Backpack® AMP with Surface Activated Amplify® Granules
In contrast, the Backpack® AMP combines surface-activated biphasic granules enclosed in a collagen pouch. This version plays a crucial role in nourishing the surgical fusion site through its unique two-component ratio of hydroxyapatite (HA) to beta-tricalcium phosphate (?TCP). By resorbing at different rates, these granules provide crucial support during the early and later stages of recovery, thus enhancing the overall effectiveness of the implant. Like the AF variant, the AMP version also comes in a ported pouch for ease of use during surgical operations.
Insights from Leadership
Russell Cook, the CEO of Ventris Medical, expressed his enthusiasm about receiving FDA clearance. He stated, "We are very pleased to receive FDA clearance for both the Backpack® AF and Backpack® AMP Bone Graft Systems. This graft containment technology is the first of its kind and represents a huge step forward in the bone graft technology available in today's market." The innovations presented by Backpack® signify a leap in how biologics can be utilized effectively in the operating room.
John Brunelle, PhD and COO of Ventris Medical, elaborated on the company’s vision: "The Backpack® technology platform is our latest venture in enhancing the surgeon experience and fusion outcomes. The sophisticated design of the containment system allows for precise delivery and retention of our clinically validated biphasic granules and allograft fibers." This vision underlines Ventris Medical's commitment to positioning itself as a leader in the evolving orthobiologics landscape.
About Ventris Medical
Ventris Medical is dedicated to pushing the boundaries of medical technology through the development of pioneering platforms for tissue regeneration and bioresorbable bone graft products. Their work focuses on addressing a wide array of spinal and orthopedic fusion procedures. As the company continues to innovate, it seeks to improve surgical practices and patient outcomes significantly.
Frequently Asked Questions
What is the significance of the FDA clearance for Backpack®?
The FDA clearance validates the safety and efficacy of Backpack® Bone Graft, allowing its use in surgical procedures and enhancing patient care through advanced technology.
How do the Backpack® AF and AMP products differ?
The Backpack® AF features osteoinductive allograft fibers, while the Backpack® AMP contains biphasic granules for varied resorption rates, catering to different healing stages in spinal surgery.
What are the benefits of using Backpack® in surgery?
Backpack® offers enhanced healing through its innovative materials that support bone growth and significantly simplify the surgical process for medical teams.
Who is behind Ventris Medical?
Ventris Medical is led by a team of experienced professionals including CEO Russell Cook, who aims to revolutionize orthobiologics and improve surgical outcomes.
What future innovations can we expect from Ventris Medical?
Ventris Medical is committed to ongoing research and development to bring forth new technologies and products that will further advance surgical practices and patient recovery.
